Overactive bladder OAB) is a condition in which the bladder muscle contracts too often and causes urinary frequency, urgency, and incontinence. It affects both men and women, but is more common in women. The causes of overactive bladder include neurological disorders, such as stroke, multiple sclerosis and eak pelvic muscles, diabetes, urinary tract infections, excess consumption of caffeine or alcohol, declining cognitive function due to aging, difficulty walking. The most common symptoms of overactive bladder include urinary urgency, frequency of urination, urge incontinence and nocturia.
Download PDF Sample Pages to Get an in-depth Assessment of the Emerging Therapies
and Key Companies:https://www.globalinsightservices.com/request-sample/GIS31214
As per Global Insight services’ assessment, about 20+ prominent pharma and biotech giants are
working on 20+ drugs in the Progressive Supranuclear Palsy – pipeline landscape globally.
Progressive Supranuclear Palsy Pipeline Insight, 2023" report by Global Insight Services
provides a comprehensive analysis of the ongoing clinical development activities and growth
prospect.
Healthcare provider will look for contributing factors using medical history, physical exam, urine sample to test for infection. Healthcare provider may also recommend urodynamic tests including measuring urine left in the bladder, measuring urine flow rate and testing bladder pressures.Overactive bladder treatment include behavioral therapies, medications, bladder injections, percutaneous tibial nerve stimulation (ptns) and surgery.
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Overactive Bladder treatment such as DA-8010, JLP-2002, YM178 and others. Key players involved in the development of therapies to treat Overactive Bladder are Astellas Pharma Inc, Bayer, Dong-A ST Co Ltd, Jeil Pharmaceutical Co Ltd, Taiho Pharmaceutical Co Ltd and others. Three drugs are under late-stage Phase III clinical trials and three drugs are in Phase II clinical trials and some other drugs are under Phase I, preclinical and discovery stages of development.
Global Insight Service’s, Overactive Bladder (OAB) – Drug Pipeline Landscape, 2023 report provides an overview of the Overactive Bladder pipeline drugs. This report covers detailed insights on Overactive Bladder (OAB) drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Overactive Bladder (OAB) pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Get Customized report as per your requirements –
https://www.globalinsightservices.com/request-customization/GIS31214
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Report Segmentation
- Assessment by Stage of Development
- Assessment by Companies
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Molecule Type
- Assessment by Route of Administration
Key Players
- Aardvark Therapeutics Inc
- Astellas Pharma Inc
- Bayer
- DelNova
- Dong-A ST Co., Ltd.
- DongKoo Bio & Pharma Co Ltd
- Exxel Pharma Inc
- Hugel
- Imbrium Therapeutics
- Jeil Pharmaceutical Co., Ltd.
- Korea United Pharm Inc
- Pantherics Inc
- PeLeMed Co Ltd
- Sea4Us
- Taiho Pharmaceutical Co., Ltd.
- Urovant Sciences GmbH
Buy your copy now:https://www.globalinsightservices.com/checkout/single_user/GIS31214
Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development
Like –
– Late-stage products (Phase III)
– Mid-stage products (Phase II)
– Early-stage product (Phase I)
– Pre-clinical and Discovery stage candidates
– Discontinued & Inactive candidates
About Global Insight Services:
Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.
Contact Us:
Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: info@globalinsightservices.com
Phone: +1-833-761-1700